Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
Bristol-Myers Squibb (Switzerland) · Tokyo Institute of Technology
Abstract
Thalidomide and the immunomodulatory drug, lenalidomide, are therapeutically active in hematological malignancies. The ubiquitously expressed E3 ligase protein cereblon (CRBN) has been identified as the primary teratogenic target of thalidomide. Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes. CRBN mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as lenalidomide- and pomalidomide-induced cytokine production in T cells. Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing…
Citation impact
- FWCI
- 22.17
- Percentile
- 100%
- References
- 32
Authors
20Topics & keywords
- Cereblon
- Pomalidomide
- Lenalidomide
- Thalidomide
- Multiple myeloma
- Cancer research
- Pharmacology
- Biology
- Good health and well-being